Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.69 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.56 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7553813 | 0.91 | CCR2 (0.70) | CCR2DGAT1KCNH2SOAT1NPBWR1 | |
| SCHEMBL7548595 | 0.87 | CCR2 (0.73) | CCR2ACHE | |
| SCHEMBL7160131 | 0.86 | CCR2 (0.74) | CCR2ACHE | |
| SCHEMBL7550045 | 0.85 | CCR2 (0.79) | CCR2ACHE | |
| SCHEMBL7549628 | 0.84 | CCR2 (0.71) | CCR2DGAT1KCNH2ACHE | |
| SCHEMBL7553543 | 0.83 | CCR2 (0.79) | CCR2ACHE | |
| SCHEMBL7549399 | 0.83 | CCR2 (0.79) | CCR2ACHE | |
| Hydrochloric Acid SCHEMBL7157093 | 0.82 | CCR2 (0.69) | CCR2ACHE | |
| SCHEMBL7554508 | 0.82 | CCR2 (0.72) | CCR2ACHE | |
| SCHEMBL7153825 | 0.82 | CCR2 (1.00) | CCR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | claimed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | claimed |
| EP-0927167-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998006703-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | CCR2 2/4885DGAT1 3365/4885KCNH2 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.